{"id":474049,"date":"2021-04-09T06:02:31","date_gmt":"2021-04-09T10:02:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474049"},"modified":"2021-04-09T06:02:31","modified_gmt":"2021-04-09T10:02:31","slug":"affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/","title":{"rendered":"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:0in\">All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">Study is continuing enrollment of the second dose cohort<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">Company to host conference call\/webcast on April 14 at 4:05 p.m. EDT<\/li>\n<\/ul>\n<p>\u00a0<\/p>\n<p>\n        <strong>Heidelberg, Germany, April 9, 2021<\/strong><br \/>\n        <em>\u2013\u00a0<\/em>Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed\u2019s innate cell engager (ICE\u00ae) AFM13 (CD16A\/CD30).\u00a0\u00a0<\/p>\n<p>This approach was developed in the laboratory of Katy Rezvani, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at MD\u00a0Anderson, who is presenting the data as part of the Major Symposia and Advances sessions at the virtual American Association for Cancer Research (AACR) Annual Meeting. The presentation is available for viewing by registered participants through June 21, 2021. Dr. Rezvani will take part in a live panel discussion as part of the presentation on April 13, 2021 at 1:30 p.m. EDT.<\/p>\n<p>\u201cWe are encouraged by the initial safety and efficacy data from this groundbreaking first in-human study. The finding of an objective response rate of 100% amongst our first four patients enrolled is impressive,\u201d said Andreas Harstrick, M.D., Chief Medical Officer of Affimed. \u201cThese initial results indicate AFM13 may have the potential to help NK cells target and destroy cancer cells. We plan to continue to develop and customize approaches that leverage the unique and differentiating features of our ICE\u00ae molecules in combination with adoptive NK cell transfer to provide options for treating a variety of hematologic and solid tumors.\u201d\u00a0 \u00a0<\/p>\n<p>The open-label, non-randomized, single-center, dose-escalation trial is evaluating the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrent\/refractory CD30-positive lymphomas. The trial is led by Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson.<\/p>\n<p>\u201cThere remains a high unmet need for effective treatments in relapsed\/refractory (R\/R) CD30+ lymphomas. We are encouraged by the data generated from the first patients treated with cbNK cells pre-complexed with AFM13,\u201d said Dr. Rezvani. \u201cThe results suggest this combination is facilitating clinical responses with minimal toxicity, warranting further study as we continue to explore novel cell therapies for our patients.\u201d \u00a0<\/p>\n<p>As of March 31, 2021, three patients have been dosed with two cycles of therapy in dose cohort 1 (1&#215;10<sup>6<\/sup> AFM13-cbNK\/kg) and one patient has received a single cycle of therapy in dose cohort 2 (1&#215;10<sup>7<\/sup> AFM13-cbNK\/kg). The study is currently enrolling patients in the second dose cohort of NK cells, and further updates are expected later in 2021. Results from the first cycle of the first dose cohort are being presented by Dr. Rezvani at AACR, and Affimed is supplementing the data with best responses as of March 31, 2021, as summarized below. <\/p>\n<table style=\"border-collapse: collapse;width:661;border-collapse:collapse\">\n<tr>\n<td style=\"width:53.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         Patient number         <\/td>\n<td style=\"width:66px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         cbNK Cell Dose         <\/td>\n<td style=\"width:78.47px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Patient          <\/td>\n<td style=\"width:75.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Cancer Type         <\/td>\n<td style=\"width:207.94px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Prior Treatment         <\/td>\n<td style=\"width:75.6px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         CRS\/ Neurotoxicity\/ GVHD         <\/td>\n<td style=\"width:103.94px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Best Response         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" style=\"width:661.2px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         Cohort 1 \u2013 completed         <\/td>\n<\/tr>\n<tr>\n<td style=\"width:53.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         #1         <\/td>\n<td style=\"width:66px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         1&#215;10<sup>6 <\/sup>\/ kg         <\/td>\n<td style=\"width:78.47px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         43-year-old-male         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Hodgkin lymphoma         <\/td>\n<td style=\"width:207.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         4 lines of therapy (ABVD, ICE, brentuximab vedotin, nivolumab + ruxolitinib)         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         None         <\/td>\n<td style=\"width:103.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Partial response          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:53.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         #2         <\/td>\n<td style=\"width:66px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         1&#215;10<sup>6 <\/sup>\/ kg         <\/td>\n<td style=\"width:78.47px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         31-year-old-male         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Hodgkin lymphoma         <\/td>\n<td style=\"width:207.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         14 lines of therapy (ABVD, brentuximab vedotin, HDACi\/P13Ki, pembrolizumab, nivolumab, allo-HSCT, hypercytoxan, ibrutinib, niraparib, bendamustine, everolimus)         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         None         <\/td>\n<td style=\"width:103.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Partial response          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:53.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         #3         <\/td>\n<td style=\"width:66px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         1&#215;10<sup>6 <\/sup>\/ kg         <\/td>\n<td style=\"width:78.47px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         53-year-old-female         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Hodgkin lymphoma         <\/td>\n<td style=\"width:207.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         5 lines of therapy (ABVD, ICE, brentuximab vedotin, nivolumab, GemOx)         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         None         <\/td>\n<td style=\"width:103.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Complete response after cycle 2         <\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" style=\"width:661.2px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         Cohort 2 \u2013 ongoing (1 of 3 patients enrolled)         <\/td>\n<\/tr>\n<tr>\n<td style=\"width:53.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">         #4         <\/td>\n<td style=\"width:66px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         1&#215;10<sup>7 <\/sup>\/ kg         <\/td>\n<td style=\"width:78.47px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         26-year-old-male         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Hodgkin lymphoma         <\/td>\n<td style=\"width:207.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         9 lines of therapy (ABVD, ICE + brentuximab vedotin, radiation, nivolumab, CD30-CART, TTI-622, brentuximab vedotin + bendamustine, allo-HSCT, brentuximab vedotin + bendamustine with brentuximab vedotin maintenance)         <\/td>\n<td style=\"width:75.6px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         None         <\/td>\n<td style=\"width:103.94px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">         Complete response          <\/td>\n<\/tr>\n<\/table>\n<p>ABVD = Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine (DTIC)<br \/>ICE = chemotherapy\u00a0combination includes the drugs: ifosfamide, carboplatin, &amp; etoposide phosphate<br \/>GemOx= gemcitabine, oxaliplatin<\/p>\n<p>There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease.<\/p>\n<p>Response evaluation followed the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC). \u00a0All four patients had relapsed\/refractory Hodgkin Lymphoma and were heavily pretreated, with between 4 and 14 previous lines of therapy which in all cases included brentuximab vedotin (Adcetris\u00ae) and anti-PD1 antibodies. Of note, patient #4 had also previously received a CD30-CAR-T. \u00a0<\/p>\n<p>\n        <strong>Conference Call\/Webcast Details<\/strong><br \/>\n        <br \/>Affimed will host a conference call and webcast on April 14, 2021, at 4:05 p.m. EDT to discuss the initial study findings. The conference call will be available via phone and webcast. To access the call, please dial +1 (646) 741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference passcode 1788338 approximately 15 minutes prior to the call.<br \/>A live audio webcast of the conference call will be available in the \u201cWebcasts\u201d section on the \u201cInvestors\u201d page of the Affimed website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ag-nKRNVUHnnKpowj5nE8asMZ4y6J__tKwcw76AtAAneC2d4cCsrpAbs4SGGQVXV8HLXkvAQ0KBGaaOUNVed10fsN06ijdYFDwiMfojA3SXHgvgmeFXnii-bLtkFPYv_lRDTvDA5-oQRsSob7mCcBWLQIgWgbwFpXjyV3D7CutY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/www.affimed.com\/investors\/webcasts_cp\/<\/u><\/a>. A replay of the webcast will be accessible at the same link for 30 days following the call.<\/p>\n<p>\n        <strong>About the Phase 1 Study<\/strong><br \/>\n        <br \/>The University of Texas MD Anderson Cancer Center is studying AFM13 in an investigator-sponsored Phase 1 trial in combination with cord blood-derived allogeneic NK cells in patients with recurrent or refractory CD30-positive lymphomas. The study is a dose-escalation trial of pre-complexed NK cells, with patients receiving 1&#215;10<sup>6 <\/sup>NK cells\/kg in Cohort 1; 1&#215;10<sup>7 <\/sup>NK cells\/kg in Cohort 2; and, 1&#215;10<sup>8 <\/sup>NK cells\/kg in Cohort 3. The trial is designed to explore safety and activity and determine the recommended Phase 2 dose. In each cohort, the dose of the pre-complexed NK cells with AFM13 is to be followed by weekly doses of 200 mg AFM13 monotherapy for three weeks, with each patient evaluated for dose-limiting toxicities and responses on day 28. Additional information about the study can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KAYDMXlVJBnpr_vlT6Hw5r4VOBpMxrsrsyzXHBFiabo8aDL0ScUg2ATYfGhZGCw9SuX8L6h-GmQGGCMOiMof8UkQc-_XpKO_2bhrZFKHP4w=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.clinicaltrials.gov<\/u><\/a> (NCT04074746).<\/p>\n<p>MD Anderson has an institutional financial conflict of interest with Affimed related to this research and has therefore implemented an Institutional Conflict of Interest Management and Monitoring Plan.<\/p>\n<p>\n        <strong>About AFM13 <\/strong><br \/>\n        <br \/>AFM13 is a first-in-class innate cell engager (ICE\u00ae) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is Affimed\u2019s most advanced ICE\u00ae clinical program and is currently being evaluated as a monotherapy in a registration-directed trial in patients with relapsed\/refractory peripheral T-cell lymphoma or transformed mycosis fungoides (REDIRECT). The study is actively recruiting, and additional details can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KAYDMXlVJBnpr_vlT6Hw5r4VOBpMxrsrsyzXHBFiabrusulB7M1aSMmC52XUro9MG5ggLHO-iLugSMHcWbmYByAiPH5jKVIphTVRNVXsjd8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.clinicaltrials.gov<\/u><\/a> (NCT04101331).<\/p>\n<p>\n        <strong>About Affimed N.V.<\/strong><br \/>\n        <br \/>Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company\u2019s proprietary ROCK\u00ae platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE\u00ae) molecules, which use patients\u2019 immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE\u00ae. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients\u2019 lives. For more about the company\u2019s people, pipeline and partners, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KAYDMXlVJBnpr_vlT6Hw5nzgJ7A7zxanyrf6KB9a7KkHBsrSrVjl1F0QSqp4UPTPew5bB1bLDjOAvp5fX4uTWA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.affimed.com<\/u><\/a>. <\/p>\n<p><strong>FORWARD-LOOKING STATEMENTS<\/strong><br \/>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook forward to,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM13, including with cbNK cells, the value of our ROCK\u00ae platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation, and the risks, uncertainties and other factors described under the heading \u201cRisk Factors\u201d in Affimed\u2019s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.\u00a0<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>Alexander Fudukidis<br \/>Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DuWz9oylAs-pzqSbZAJw_yeNRofZMZUsZ3NbO1dViiKFelxRLEmGYJL5ZNCSaD0axKdfTDKBGI_Didry4Wy9jnsgCBQrw9igHpdw5nm4vE4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>a.fudukidis@affimed.com<\/u><\/a><br \/>Tel.: +1 (917) 436-8102<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Mary Beth Sandin<br \/>Head of Marketing and Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sy8scN1fPPe3_OMAtsda9ksYy5VskQkr0NH16i_nH3K-23YcEYag6VyzrmEpB0HYSkKqKSujGLNO2QSYAcl6tPtRFqVwDTRttSmItp5w3Ck=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>m.sandin@affimed.com<\/u><\/a><br \/>Tel.: +1 (484) 888-8195<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/200025e2-7570-409c-a05d-f56a159e724a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease Study is continuing enrollment of the second dose cohort Company to host conference call\/webcast on April 14 at 4:05 p.m. EDT \u00a0 Heidelberg, Germany, April 9, 2021 \u2013\u00a0Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed\u2019s innate cell engager &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-474049","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u00a0 All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease Study is continuing enrollment of the second dose cohort Company to host conference call\/webcast on April 14 at 4:05 p.m. EDT \u00a0 Heidelberg, Germany, April 9, 2021 \u2013\u00a0Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed\u2019s innate cell engager &hellip; Continue reading &quot;Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-09T10:02:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13\",\"datePublished\":\"2021-04-09T10:02:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/\"},\"wordCount\":1534,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/\",\"name\":\"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==\",\"datePublished\":\"2021-04-09T10:02:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/","og_locale":"en_US","og_type":"article","og_title":"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Market Newsdesk","og_description":"\u00a0 All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease Study is continuing enrollment of the second dose cohort Company to host conference call\/webcast on April 14 at 4:05 p.m. EDT \u00a0 Heidelberg, Germany, April 9, 2021 \u2013\u00a0Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed\u2019s innate cell engager &hellip; Continue reading \"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-09T10:02:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13","datePublished":"2021-04-09T10:02:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/"},"wordCount":1534,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/","name":"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==","datePublished":"2021-04-09T10:02:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ3NzM3NCM0MDA5MDg2MDQjMjAwMzczNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=474049"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474049\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=474049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=474049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=474049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}